521-34-6

521-34-6 structure

Name: Amentoflavone-4',4",7-trimethyl Ether
Chemical Name: sciadopitysin
CAS Number: 521-34-6
Molecular Formula: C₃₃H₂₄O₁₀
Molecular Weight: 580.538
Catalog: Natural product Flavonoids
Create Date: 2018-07-13 16:28:11
Modify Date: 2024-01-05 18:27:35
Sciadopitysin is a type of biflavonoids in leaves from ginkgo biloba[1]. Sciadopitysi inhibits RANKL-induced osteoclastogenesis and bone loss by inhibiting NF-κB activation and reducing the expression of c-Fos and NFATc1[2].

Name	sciadopitysin
Synonyms	Amentoflavone-4',4",7-trimethyl Ether I-7,I-4',II-4'-tri-O-methylamentoflavone Amentoflavone-7,4',4'''-trimethyl ether 5,7-Dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxo-4H-chromen-2-yl)-2-methoxyphenyl]-2-(4-methoxyphenyl)-4H-chromen-4-one Sciadopitysin 5,7-dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxochromen-2-yl)-2-methoxyphenyl]-2-(4-methoxyphenyl)chromen-4-one 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-yl)-2-methoxyphenyl]-2-(4-methoxyphenyl)- Sciadopytissin Jin Song biflavone

Description	Sciadopitysin is a type of biflavonoids in leaves from ginkgo biloba[1]. Sciadopitysi inhibits RANKL-induced osteoclastogenesis and bone loss by inhibiting NF-κB activation and reducing the expression of c-Fos and NFATc1[2].
Related Catalog	Research Areas >> Inflammation/Immunology
Target	NF-κB
In Vitro	Sciadopitysin (2.5, 5, 10 μM ) strongly reduces RANKL-induced osteoclast-specific genes expression, including cathepsin K (CTSK), tartrate-resistant acid phosphatase (TRAP) and MMP-9. Furthermore, Sciadopitysin apparently attenuates RANKL-increased expressions of c-Fos and NFATc1[2].
In Vivo	Sciadopitysin (i.p.; 10 mg/kg; every other day for 8 days) can reverse the bone loss in LPS-induced mice model (C57BL/6 mice; 6 weeks old)[2].
References	[1]. Briançon-Scheid F, et al. HPLC Separation and Quantitative Determination of Biflavones in Leaves from Ginkgo biloba. Planta Med. 1983 Dec;49(12):204-7. [2]. Sciadopitysin suppresses RANKL-mediated osteoclastogenesis and prevents boneloss in LPS-treated mice. Int Immunopharmacol. 2017 Aug;49:109-117.